CIZ1B Biomarker Blood Test
Early Detection of Lung Cancer
Clinical ValidationActive
Key Facts
Indication
Early Detection of Lung Cancer
Phase
Clinical Validation
Status
Active
Company
About Cizzle Biotechnology
Cizzle Biotechnology is on a mission to transform lung cancer survival rates through early detection. The company's core innovation is a simple blood test that detects the CIZ1B biomarker with high sensitivity, offering a more accessible and affordable alternative to current CT scan-based screening. Publicly listed and backed by research from the University of York, Cizzle is progressing through clinical validation and building partnerships to commercialize its life-saving diagnostic technology globally.
View full company profile